Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies

NCT03722186 · clinicaltrials.gov ↗

PHASE1

Phase

SUSPENDED

Status

128

Enrollment

INDUSTRY

Sponsor class

Stopped Business Decision

Conditions

Physiological Effects of Drugs
Neoplasms by Histologic Type
Lymphoma
Hematologic Neoplasms
Immunotherapy
Advanced Cancer

Interventions

DRUG: SHR-1603

Sponsor

Jiangsu HengRui Medicine Co., Ltd.